Ramipril for Memory Loss in Glioblastoma Patients

Palo Alto (17 mi)

Overseen byMichael D Chan, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Prior Safety Data

Approved in 5 jurisdictions

Trial Summary

What is the purpose of this trial?This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.

Eligibility Criteria

This trial is for adults with glioblastoma who are about to receive chemoradiation. They must have proper kidney, liver, and blood function, no prior use of ACE inhibitors or certain cancer treatments, and cannot be pregnant. Participants should not have other serious medical conditions that could interfere with the study.

Inclusion Criteria

My diagnosis of glioblastoma or gliosarcoma was confirmed through surgery, not just a needle biopsy.

I will start the study drug between 3 to 6 weeks after my surgery.

My tumor is located in the upper part of my brain.

I can take care of myself and am up and about more than half of my waking hours.

I can complete tests in English.

I had cancer before, but I finished treatment over 2 years ago and am now cancer-free.

Exclusion Criteria

I haven't had certain cancer treatments like chemotherapy or radiation to specific areas.

I am not planning to receive extra cancer treatments besides standard radiation and temozolomide.

My brain cancer has come back or is in multiple places.

I have only one kidney or a narrowed kidney artery.

My cancer has spread to the lower part of my brain or beyond.

I am unable to make medical decisions for myself.

My kidneys are not working well, with a creatinine clearance below 40 ml/min.

I am not pregnant and willing to use contraception if of childbearing potential.

Treatment Details

The trial tests if Ramipril can prevent memory loss in glioblastoma patients undergoing chemoradiation. Patients will take Ramipril starting from 21 to 42 days after surgery until four months post-treatment while their memory is monitored using neurocognitive tests.

1Treatment groups

Experimental Treatment

Group I: RamiprilExperimental Treatment1 Intervention

Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).

Ramipril is already approved in United States, Canada, European Union, India for the following indications:

🇺🇸 Approved in United States as Altace for: